Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs JTCR 016 (Primary) ; Aldesleukin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020.
- 03 Nov 2017 Status changed from suspended to recruiting.
- 27 Jul 2017 Patients with myelodysplastic syndromes and acute-myeloid-leukaemia will no longer be considered eligible for the study.